Intellia Therapeutics, Inc.’s NTLA-2002 holds a strong position as it heads into Phase III development for hereditary angioedema (HAE), with Phase II data showing a high rate of functional cure. However, three patients continued to experience what could be HAE attacks.
Intellia Moves Into Phase III With NTLA-2002, But Concerns Remain
The gene-editing therapy produced functional cures in eight of 11 patients receiving the go-forward 50mg dose, but the rate fell short of what some investors had hoped for.
